This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
vaccines: Archive
ImmunoGen (IMGN) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
IMGNPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Novavax (NVAX) Further Delays FDA Filing for COVID-19 Vaccine
by Zacks Equity Research
Novavax's (NVAX) filing with the FDA seeking approval for emergency use authorization of its COVID-19 vaccine, NVX-CoV2373, gets further postponed to January 2022.
JNJPositive Net Change PFEPositive Net Change MRNAPositive Net Change NVAXPositive Net Change
biotechs medical vaccines
Here's Why Pfizer (PFE) Appears Strongly Placed for 2022
by Kinjel Shah
While the COVID vaccine should continue to boost Pfizer (PFE) revenues in 2022, Paxlovid is also likely to become an important top-line driver
PFEPositive Net Change ARNAPositive Net Change MRKNegative Net Change BNTXNegative Net Change
biotechnology vaccines
J&J (JNJ) COVID Booster Jab Shows Effectiveness Against Omicron
by Zacks Equity Research
Johnson & Johnson's (JNJ) COVID booster vaccine demonstrates 85% effectiveness against COVID-related hospitalization in South Africa, with Omicron becoming the dominant variant.
JNJPositive Net Change PFEPositive Net Change MRNAPositive Net Change BNTXNegative Net Change
medical pharmaceuticals vaccines
Ocugen (OCGN) Up on Bharat Biotech's Data in Pediatric Group
by Zacks Equity Research
Ocugen (OCGN) gains on Bharat Biotech's positive results from a study in the pediatric population.
PFEPositive Net Change NVAXPositive Net Change OCGNNo Net Change BNTXNegative Net Change
biotechnology biotechs medical pharmaceuticals vaccines
Jobless Claims Steady at Pre-Covid Levels
by Mark Vickery
For the third time in six weeks, Initial Jobless Claims have come in below the psychologically satisfying 200K number: 198K.
ADPNegative Net Change QQQPositive Net Change SPYPositive Net Change DIAPositive Net Change
finance staffing vaccines
After Golden Cross, Entergy (ETR)'s Technical Outlook is Bright
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
ETRNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Follow The Leader: 3 Biopharma Stocks Displaying Relative Strength
by Bryan Hayes
3 Biopharma Stocks Displaying Relative Strength Heading Into 2022
REGNNegative Net Change GILDNegative Net Change CDMOPositive Net Change
biotechnology biotechs cancer cell-therapy coronavirus earnings gene-therapy genetics hospitals immuno-therapy investing medical oncology-screening pharmaceuticals smart-health vaccines
Novavax (NVAX) COVID Jab Gets Nod for Emergency Use in India
by Zacks Equity Research
Novavax (NVAX) secures approval in India for emergency use of its COVID-19 vaccine.
AZNNegative Net Change PFEPositive Net Change NVAXPositive Net Change BNTXNegative Net Change
biotechs medical vaccines
Are Markets Avoiding Omicron or Seeing Through It?
by Mark Vickery
The panic-selling that came the day after Thanksgiving and burned through the following week has flamed out.
QQQPositive Net Change SPYPositive Net Change DIAPositive Net Change
finance vaccines
Black Knight (BKI)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
BKINegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
3 Biotech Stocks Worth Adding to Your Portfolio Next Year
by Ekta Bagri
Here we present three biotech companies, which are likely to perform well in 2022, backed by strong fundamentals.
BIIBNegative Net Change MRNAPositive Net Change RGENNegative Net Change SRPTNegative Net Change BGNEPositive Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals vaccines
Novavax (NVAX) COVID-19 Booster Jab Effective Against Omicron
by Zacks Equity Research
Novavax's (NVAX) protein-based COVID vaccine shows a cross-reactivity response against the Omicron variant. It will also start clinical studies on an Omicron-specific vaccine in first-quarter 2022.
PFEPositive Net Change MRNAPositive Net Change NVAXPositive Net Change BNTXNegative Net Change
biotechs vaccines
5 Biotech Stocks That More Than Doubled This Year
by Ekta Bagri
The biotech sector has been in focus through 2021 as vaccine makers like Moderna (MRNA) BioNTech (BNTX), and other companies like Dynavax (DVAX), Prothena (PRTA) and Intellia (NTLA) put up an exemplary performance.
DVAXNegative Net Change MRNAPositive Net Change PRTAPositive Net Change NTLAPositive Net Change BNTXNegative Net Change
biotechnology biotechs crispr gene-editing medical vaccines
Biotech Stock Roundup: Regulatory Updates From BIIB, AMGN and NVAX & More
by Zacks Equity Research
Regulatory and other pipeline updates from Biogen (BIIB) and Novavax (NVAX) have been the biotech sector's few key highlights during the past week.
BIIBNegative Net Change AMGNNegative Net Change GILDNegative Net Change NVAXPositive Net Change VIRPositive Net Change
biotechs medical pharmaceuticals vaccines
Should You Buy Arena Pharmaceuticals, Inc. (ARNA) After Golden Cross?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
ARNAPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Novavax (NVAX) Commences COVID-19 Vaccine Booster Study
by Zacks Equity Research
Novavax (NVAX) initiates a phase III study to evaluate the booster dose of its COVID vaccine. WHO recommends administering the company's COVID vaccine booster to immunocompromised persons.
JNJPositive Net Change PFEPositive Net Change MRNAPositive Net Change NVAXPositive Net Change
biotechs medical vaccines
Novavax (NVAX) COVID Vaccine Gets EU Nod, 2nd Listing by WHO
by Zacks Equity Research
Novavax (NVAX) secures approval for its COVID vaccine in the European Union. Following EU approval, WHO grants second emergency use listing to the company's COVID vaccine.
JNJPositive Net Change PFEPositive Net Change MRNAPositive Net Change NVAXPositive Net Change
biotechs medical vaccines
Novavax (NVAX) COVID Jab Gets WHO Nod for Emergency Use Listing
by Zacks Equity Research
Novavax's (NVAX) COVID-19 vaccine gets approval from WHO for emergency use listing. The vaccine is now pre-qualified for supply to numerous countries participating through the COVAX facility.
GSKPositive Net Change NVAXPositive Net Change RGENNegative Net Change ISEEPositive Net Change
biotechs medical vaccines
Merck's (MRK) Pneumococcal Vaccine Vaxneuvance Gets EU Nod
by Zacks Equity Research
Merck's (MRK) Vaxneuvance includes pneumococcal serotypes 22F and 33F, which are not included in the currently licensed 13-valent conjugate vaccines.
GSKPositive Net Change RHHBYPositive Net Change PFEPositive Net Change MRKNegative Net Change
pharmaceuticals vaccines
Pfizer, BioNTech Booster Gets FDA Nod for 16- & 17-Year Olds
by Zacks Equity Research
FDA authorizes the booster shot of Pfizer (PFE) and BioNTech's (BNTX) COVID-19 vaccine for 16- and 17-year olds.
JNJPositive Net Change PFEPositive Net Change MRNAPositive Net Change BNTXNegative Net Change
pharmaceuticals vaccines
Pharma Stock Roundup: PFE Booster Works on Omicron, AZN COVID Cocktail Gets FDA Nod
by Kinjel Shah
Pfizer (PFE) and BioNTech's COVID-19 booster shot proves effective against the Omicron variant. FDA grants EUA to AstraZeneca's (AZN) cocktail antibody for pre-exposure prophylaxis (prevention) of COVID-19.
AZNNegative Net Change PFEPositive Net Change MRKNegative Net Change LLYNegative Net Change ABBVNegative Net Change
pharmaceuticals vaccines
Remedies for Omicron Apparent, Markets Up Again
by Mark Vickery
New forms of Covid-19 appear to be growing more highly infectious, if not necessarily more life-threatening.
JNJPositive Net Change PFEPositive Net Change MRKNegative Net Change ILMNPositive Net Change MRNAPositive Net Change GMEPositive Net Change BNTXNegative Net Change
finance medical vaccines
Vaccine Stocks Down as Omicron May Not Be Too Severe
by Kinjel Shah
Stocks of Moderna (MRNA), BioNTech (BNTX), Novavax (NVAX) and Pfizer (PFE) decline as data suggests that Omicron variant may cause less severe cases of COVID-19.
PFEPositive Net Change MRKNegative Net Change MRNAPositive Net Change NVAXPositive Net Change BNTXNegative Net Change
biotechnology vaccines
How Disruptive Will Omicron Be? Global Week Ahead
by John Blank
How disruptive will the Omicron COVID variant prove to be for the world economy? That's a lead question U.S. and Global stock markets grapple with.
JDNegative Net Change TTDKYPositive Net Change AUOTYPositive Net Change
emerging-markets vaccines